News about "Antibody-Drug Conjugate "

GSK Gains Exclusive Rights to Syndivia's Prostate Cancer ADC

GSK has obtained exclusive rights from Syndivia for a preclinical Antibody-Drug Conjugate (ADC) targeting metastatic Castration-Resistant Prostate Cancer (mCRPC), addressing an urgent need for novel therapies. The agreement expands GSK’s oncology pipeline with a potential best-in-class ADC designed to deliver enhanced anti-tumour activity.

Antibody Drug Conjugate | 27/10/2025 | By Dineshwori |  125

CDSCO approves AstraZeneca's Trastuzumab Deruxtecan for More HER2-Positive Tumours

With this, Trastuzumab Deruxtecan becomes India’s first Antibody Drug Conjugate (ADC) approved for a tumour-agnostic indication.

Antibody Drug Conjugate | 04/10/2025 | By Dineshwori |  176

US FDA Grants Priority Review for Enhertu + Pertuzumab in HER2+ Metastatic Breast Cancer

The US FDA has granted Priority Review to Enhertu + Pertuzumab for HER2+ metastatic breast cancer, following DESTINY-Breast09 trial results showing a 44 percent reduction in risk of disease progression or death and over three years’ median Progression-Free Survival (PFS), positioning it as a potential new first-line standard of care.

Antibody Drug Conjugate | 25/09/2025 | By Dineshwori

FDA Grants BTD to Raludotatug Deruxtecan for Platinum-Resistant Ovarian Cancer

This is the first BTD granted for Raludotatug Deruxtecan, the second for the Daiichi Sankyo-Merck partnership and the 15th across Daiichi Sankyo’s oncology portfolio, marking a significant milestone in the companies’ joint efforts to develop innovative cancer therapies.

Antibody-Drug Conjugate | 16/09/2025 | By Dineshwori |  103

LOTTE BIOLOGICS Enters Contract Manufacturing Partnership with US Biopharma

South Korea’s LOTTE BIOLOGICS has signed a late-stage to commercial contract manufacturing agreement with a US-based global biopharmaceutical company.

Antibody-Drug Conjugate | 02/09/2025 | By Dineshwori |  243

Cohance Lifesciences to Invest USD 10 Million to Expand cGMP Bioconjugation Capabilities in US

Cohance Lifesciences will invest USD 10 million to expand cGMP bioconjugation capabilities at its US-based subsidiary NJ Bio, strengthening its integrated Antibody-Drug Conjugate manufacturing capacity for global innovators.

Antibody-Drug Conjugate | 13/08/2025 | By Mrinmoy Dey |  161

SPARC Incorporates Wholly Owned Subsidiary Genokine Biotech in Vadodara

Sun Pharma Advanced Research Company Ltd. (SPARC) has incorporated a new wholly owned subsidiary, Genokine Biotech Ltd., with its registered office in Vadodara, Gujarat.

Antibody-drug Conjugate | 09/07/2025 | By Dineshwori |  291

SPARC Submits IND Application for SBO-154 to USFDA

Sun Pharma Advanced Research Company Ltd. (SPARC) has submitted an IND application to the US FDA for SBO-154, a novel antibody-drug conjugate (ADC) targeting advanced solid tumours.

Antibody-drug Conjugate | 31/03/2025 | By Aishwarya |  233

Innovent Signs Exclusive Global License Deal with Roche for Novel DLL3 Antibody Drug Conjugate

IBI3009 targets DLL3, an antigen with low expression in normal tissues but significantly overexpressed in certain cancers, particularly small-cell lung cancer and other neuroendocrine tumors.

Antibody Drug Conjugate | 02/01/2025 | By Aishwarya |  263

Samsung Biologics Announces Manufacturing Deal with European Pharmaceutical Company

Samsung Biologics is set to add antibody-drug conjugate (ADC) services to its portfolio, with a dedicated facility to be completed by the end of this year.

Antibody-drug Conjugate | 20/11/2024 | By Aishwarya |  251